Skip to main content

Advertisement

Table 3 Ex vivo stability data for doxorubicin (DOX)

From: Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles

Conditions LQC (2.90 ng/ml) HQC (2000.00 ng/ml)
Long term stability; recovery (ng) after storage (− 40 °C)
 Previous day 2.83 ± 0.05 1989.04 ± 5.16
 30th day 2.79 ± 0.04 (98.59%) 1951.78 ± 19.12 (98.13%)
Freeze–thaw stress; recovery (ng) after freeze–thaw cycles (− 40 to 25 °C)
 Pre-cycle 2.84 ± 0.03 1988.10 ± 4.19
 First cycle 2.80 ± 0.04 (98.59%) 1976.19 ± 12.91 (99.40%)
 Second cycle 2.78 ± 0.04 (97.88%) 1972.54 ± 13.16 (99.22%)
 Third cycle 2.74 ± 0.05 (96.48%) 1966.44 ± 13.67 (98.91)
Heating–cooling stress; recovery (ng) after heating–cooling cycles (50–4 °C)
 Pre-cycle 2.85 ± 0.03 1989.09 ± 5.90
 First cycle 2.80 ± 0.04 (98.25%) 1981.61 ± 11.95 (99.62%)
 Second cycle 2.76 ± 0.03 (96.84%) 1974.01 ± 12.04 (99.24%)
 Third cycle 2.72 ± 0.03 (95.44%) 1963.02 ± 13.02 (98.69%)
Bench top stability; recovery (ng) at room temperature (25 °C)
 0 h 2.84 ± 0.03 1988.49 ± 11.01
 24 h 2.80 ± 0.05 (98.59%) 1969.10 ± 12.31 (99.02%)
Post processing stability; recovery (ng) after storage in auto sampler (4 °C)
 0 h 2.85 ± 0.03 1979.02 ± 7.91
 24 h 2.81 ± 0.04 (99.60%) 1962.01 ± 14.02 (99.14%)
  1. Values (Mean ± SD) are derived from six replicates. Figures in parenthesis represent analyte concentration (%) relative to time zero. Theoretical contents; LOQQC: 1.01 ng/ml, LQC: 2.9 ng/ml; MQC: 1000 ng/ml; and HQC: 2000 ng/ml